GRI Bio Corp (GRI) - Business Payback Period
The price chart for GRI Bio, Inc. (GRI) illustrates the price action of an asset currently valued at -0.40. The business relies on the development of NKT cell modulators under strict FDA oversight and in the absence of stable sales. Long-term contracts with bio-factories ensure production stability by eliminating raw material shortages. However, the risk of losing market position remains high due to patent disputes with biotech behemoths.
Analytical breakdowns for GRI Bio, Inc.
- share price and expert price forecast:
- market capitalization indicators:
- book capitalization data:
- company liabilities and liquidity data:
- company profitability and valuation multiples indicators:
GRI - Net Profit|Company Profit Forecast GRI Bio, Inc.|GRI - Price to Earnings Ratio|Future Price to Earnings Multiple GRI Bio Inc|GRI - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GRI Bio, Inc.|GRI - Operating profit EBITDA|Net earnings per share for the last four quarters GRI Bio|GRI - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months gribio.com|GRI - Net earnings per share growth this year|Expected earnings per share trend next year GRI Bio, Inc.
Summary company analysis:GRI (gribio.com)
The scalability of GRI Bio, Inc. (GRI) biopharmaceutical platforms is directly reflected in the dynamics of the company's P/E valuation profile. This ratio compares market capitalization to net income, determining the cost of one dollar of earnings. The metric reveals capital density and the order balance influencing quotes. High values often signal that the asset is overbought ahead of a potential correction. Investors should evaluate this indicator as a marker of the efficiency of monetizing technological advantages.
Key competitors
ARGX: Company Value to Net Income|P/E Multiple BNTX|Business Payback Period ABIVAX|Price to Earnings Ratio ADMA Bio ADMA|PTGX - Price to Earnings Ratio|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|GRFS (Grifols) - Price to Earnings Ratio|Adaptive Biotech (ADPT) - P/E Multiple|Price to Earnings Ratio Celldex|Price to Earnings Multiple AUPH (Aurinia Corp)|P/E Multiple BCRX|VERA - Market Cap to Earnings|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Market Cap to Net Income Ratio Pharvaris NV|ABCL - Price to Earnings Ratio|Company Value to Net Income TRML (Tourmaline)|PGEN: P/E Multiple|PHAR - Business Payback Period|Price to Earnings Ratio NKTR|UPB: Company Value to Net Income|P/E Multiple ZBIO|Price to Earnings Ratio IMNM (Immunome Bio)|P/E Multiple GOSS (Gossamer Bio, Inc.)|Business Payback Period kalvista.com (KALV)|SEPN - Price to Earnings Ratio|Market Cap to Earnings Pieris Pharma|SVRA (Savara Corp) - Price to Earnings Ratio|Rigel Corp - Company Value to Net Income|ANAB (AnaptysBio, Inc.) - P/E Multiple|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio enGene (ENGN)|RAPT Therapeutics Inc. - Price to Earnings Multiple|P/E Multiple JBIO (Aerovate Therapeutics)|ACRS - Price to Earnings Ratio|KYTX: Price to Earnings Ratio|Business Payback Period tizianalifesciences.com TLSA|CABA: P/E Multiple|Market Cap to Net Income Ratio Ventyx Biosciences Inc. VTYX|Price to Earnings Ratio Theratechnologies Inc|AVTX: Company Value to Net Income|P/E Multiple ELDN|Business Payback Period agenusbio.com|Price to Earnings Ratio Climb Bio CLYM|ZURA (Zura Bio Ltd) - Market Cap to Net Income|aTyr - P/E Multiple|Company Value to Net Income ADAG (Adagene)|IMA: P/E Multiple|Shattuck Labs (STTK) - P/E Multiple|Price to Earnings Ratio Equillium Inc|CNTB: Company Value to Net Income|Price to Earnings Ratio Immunic, Inc. (IMUX)|Price to Earnings Ratio atarabio.com ATRA|P/E Multiple IFRX (InflaRx)|P/E Multiple x4pharma.com XFOR|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (Celularity Inc.)|INMB: P/E Multiple|BRNS - Business Payback Period|Price to Earnings Ratio Kezar Life Sciences|Price to Earnings Ratio sabbiotherapeutics.com (SABS)|Price to Earnings Ratio Akari Therapeutics Plc (AKTX)|Price to Earnings Ratio enlivex.com ENLV|Q32 Bio - Price to Earnings Ratio|P/E Multiple GeoVax Corp GOVX|EDSA - Price to Earnings Ratio|IBIO (ibioinc.com) - Price to Earnings Multiple|CARM: P/E Multiple|Market Cap to Earnings XTL Biopharmaceuticals Ltd (XTLB)|BOLT (Bolt Biotherapeutics Inc.) - P/E Multiple|HCWB - Market Cap to Net Income Ratio|Price to Earnings Ratio Aptevo Therapeutics (APVO)|AIM (AIM ImmunoTech, Inc.) - Company Value to Net Income|P/E Multiple ADTX (Aditxt, Inc.)|Business Payback Period XORTX Therapeutics Inc (XRTX)|HIND: Price to Earnings Ratio|Company Value to Net Income REVB (Revelation Biosciences Corp)|INDP: P/E Multiple|SCNI (scinai.com) - Price to Earnings Ratio|CALI (CalciMedica Inc) - P/E Multiple|Affimed Therapeutics (AFMD) - Business Payback Period|Price to Earnings Ratio Allakos Inc. (ALLK)|HOOK - Market Cap to Earnings|IGM Biosciences - Price to Earnings Ratio|Company Value to Net Income ITOS|Ocean Biomedical - P/E Multiple|Business Payback Period TC BioPharm (Holdings) Plc TCBP|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
